Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (281-290 of 345) with videos related to

Pageof 35
Sort By:
RMD Open|February 28, 2023
Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registersBenedicte Delcoigne, Tine Iskov Kopp, Elizabeth V Arkema, et al.
Annals of the Rheumatic Diseases|December 5, 2023
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammationEleftheria Pertsinidou, Saedis Saevarsdottir, Vivek Anand Manivel, et al.
Arthritis and Rheumatism|June 30, 2005
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in SwedenJohan Askling, C Michael Fored, Lena Brandt, et al.
RMD Open|December 23, 2022
Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort studyRene Lindholm Cordtz, Johan Askling, Benedicte Delcoigne, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 5, 2008
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitisAnnika Bergquist, Scott M Montgomery, Shahram Bahmanyar, et al.
Rheumatology (Oxford, England)|October 18, 2022
The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritisHelga Westerlind, Alf Kastbom, Johan Rönnelid, et al.
RMD Open|December 9, 2021
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provisionHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
Arthritis and Rheumatism|October 31, 2009
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?Johan Askling, Ronald F van Vollenhoven, Fredrik Granath, et al.
Annals of the Rheumatic Diseases|February 24, 2021
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort studyHannah Bower, Thomas Frisell, Daniela Di Giuseppe, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Pageof 35

Showing results (281-290 of 345) with videos related to

Sort By:
Pageof 35
RMD Open|February 28, 2023
Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registersBenedicte Delcoigne, Tine Iskov Kopp, Elizabeth V Arkema, et al.
Annals of the Rheumatic Diseases|December 5, 2023
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammationEleftheria Pertsinidou, Saedis Saevarsdottir, Vivek Anand Manivel, et al.
Arthritis and Rheumatism|June 30, 2005
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in SwedenJohan Askling, C Michael Fored, Lena Brandt, et al.
RMD Open|December 23, 2022
Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort studyRene Lindholm Cordtz, Johan Askling, Benedicte Delcoigne, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 5, 2008
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitisAnnika Bergquist, Scott M Montgomery, Shahram Bahmanyar, et al.
Rheumatology (Oxford, England)|October 18, 2022
The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritisHelga Westerlind, Alf Kastbom, Johan Rönnelid, et al.
RMD Open|December 9, 2021
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provisionHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
Arthritis and Rheumatism|October 31, 2009
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?Johan Askling, Ronald F van Vollenhoven, Fredrik Granath, et al.
Annals of the Rheumatic Diseases|February 24, 2021
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort studyHannah Bower, Thomas Frisell, Daniela Di Giuseppe, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Pageof 35